Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Randomized, Open-label, Active Controlled Study to Evaluate the Safety and Efficacy of Micafungin Salvage Mono-therapy Versus Active Control Intravenous Salvage Mono-therapy in Patients With Invasive Aspergillosis

NCT00376337 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00376337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00376337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Randomized, Open-label, Active Controlled Study to Evaluate the Safety and Efficacy of Micafungin Salvage Mono-therapy Versus Active Control Intravenous Salvage Mono-therapy in Patients With Invasive Aspergillosis
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2006
Completion date
September 30, 2008
Enrollment
17 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

invasive aspergillosis